ArticleScientific data2017
Molecular, phenotypic, and sample-associated data to describe pluripotent stem cell lines and derivatives.
Article in Scientific data, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Identification and characterization of lncRNA-stemness-immune regulatory patterns.Briefings in bioinformatics · 2026Article
- Comprehensive analysis of a machine learning prognostic model for the interaction between mitochondrial function and lactylation in lung adenocarcinoma.Discover oncology · 2025Article
- Identification of key genes regulating colorectal cancer stem cell characteristics by bioinformatics analysis.Medicine · 2025Article
- Investigating Associations Between Prognostic Factors in Gliomas: Unsupervised Multiple Correspondence Analysis.JMIR bioinformatics and biotechnology · 2025Article
- A novel stemness-related lncRNA signature predicts prognosis, immune infiltration and drug sensitivity of clear cell renal cell carcinoma.Journal of translational medicine · 2025Article
- Cancer molecular subtyping using limited multi-omics data with missingness.PLoS computational biology · 2024Article
- Stemness subtypes in lower-grade glioma with prognostic biomarkers, tumor microenvironment, and treatment response.Scientific reports · 2024Article
- Article
- Proteogenomic characterization of primary colorectal cancer and metastatic progression identifies proteome-based subtypes and signatures.Cell reports · 2024Article
- A Novel Eight-Gene Signature for Lipid Metabolism Predicts the Progression of Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma.Reproductive sciences (Thousand Oaks, Calif.) · 2024Article
- The role of VANGL2 in glioma oncogenesis and progression: insights into expression profiles and prognostic relevance.Frontiers in oncology · 2024Article
- Spatially resolved transcriptomic profiles reveal unique defining molecular features of infiltrative 5ALA-metabolizing cells associated with glioblastoma recurrence.Genome medicine · 2023Article
- Epigenetic biomarkers to track differentiation of pluripotent stem cells.Stem cell reports · 2023Article
- Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness.Cancer cell · 2023Article
- Comprehensive proteome, phosphoproteome and kinome characterization of luminal A breast cancer.Frontiers in oncology · 2023Article
- Stemness Correlates Inversely with MHC Class I Expression in Pediatric Small Round Blue Cell Tumors.Cancers · 2022Article
- Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer.Stem cell research & therapy · 2022Article
- xCT contributes to colorectal cancer tumorigenesis through upregulation of the MELK oncogene and activation of the AKT/mTOR cascade.Cell death & disease · 2022Article
- StemSC: a cross-dataset human stemness index for single-cell samples.Stem cell research & therapy · 2022Article
- βIII-Tubulin Gene Regulation in Health and Disease.Frontiers in cell and developmental biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
The use of induced pluripotent stem cells (iPSC) derived from independent patients and sources holds considerable promise to improve the understanding of development and disease. However, optimized use of iPSC depends on our ability to develop methods to efficiently qualify cell lines and protocols, monitor genetic stability, and evaluate self-renewal and differentiation potential. To accomplish these goals, 57 stem cell lines from 10 laboratories were differentiated to 7 different states, resulting in 248 analyzed samples. Cell lines were differentiated and characterized at a central laboratory using standardized cell culture methodologies, protocols, and metadata descriptors. Stem cell and derived differentiated lines were characterized using RNA-seq, miRNA-seq, copy number arrays, DNA methylation arrays, flow cytometry, and molecular histology. All materials, including raw data, metadata, analysis and processing code, and methodological and provenance documentation are publicly available for re-use and interactive exploration at https://www.synapse.org/pcbc. The goal is to provide data that can improve our ability to robustly and reproducibly use human pluripotent stem cells to understand development and disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.